Mosseri Marlio Charles

10% owner Mosseri bought 50,000 NVCT shares at $18.32 on 2026-06-30; stock now $19.47, up 99.7% in 30 days.

Mosseri, a 10% owner, purchased 50,000 shares for $916,000.00 at $18.32, increasing his holdings to 3,186,576 shares. The timing follows strong recent momentum: the stock has risen 99.7% over 30 days and 157.5% over 90 days from the transaction date, trading at $19.47 against a 52-week range of $5.55–$29.28. His prior trades at NVCT show mixed results—three of five prior buys achieved positive 90-day returns (+36.8%, +42.4%, +41.6%), though two experienced losses (-19.9%, -22.9%)—suggesting some capacity for opportunistic timing at this ticker. However, the company remains unprofitable with net income of $-6,050,000.00 and a market cap of $516,452,127.51, adding fundamental caution despite the insider's continued accumulation.

10% owner Mosseri purchases 154,770 shares for $957.1K across 3 transactions at avg $6.18, raising stake 5.2% amid unprofitable operations.

Mosseri Marlio Charles, a 10% owner at Nuvectis Pharma, executed 3 separate purchases totaling 154,770 shares for $957,083.18 (blended average $6.18/share) between October 23–27, 2025, lifting his holdings from 2,981,806 to 3,136,576 shares. The purchases occurred at prices well below the 52-week high of $10.98 and modestly below the current price of $6.77. However, his prior trade history at this ticker shows a 0% well-timed rate across 5 prior buys—all five 90-day periods ended in losses ranging from −19.9% to −26.0%—suggesting a pattern of accumulation at inflection points that have not subsequently recovered. The company reported a net loss of $6,334,000 over its most recent full fiscal year, underscoring the speculative nature of the position at a $172.3M market cap. The purchases represent a material increase in an already substantial stake, warranting examination of whether this reflects conviction in a turnaround or continued accumulation of a deeply challenged asset.

10% owner Mosseri adds 5,603 shares at $7.99 amid -18.8% 30-day decline; NVCT unprofitable, stock -27.3% from 52w high

Mosseri, a 10% owner, purchased 5,603 shares at $7.99 on 2025-06-20, increasing holdings to 2,981,806 shares. This transaction occurred as the stock was down 18.8% over the prior 30 days and 27.3% below its 52-week high of $10.98. The company reported net income of -$5,332,000 in its most recent fiscal period, indicating ongoing unprofitability. Notably, Mosseri executed two prior purchases at NVCT on 2025-06-18 and 2025-06-17 (immediately preceding this transaction), suggesting a deliberate accumulation pattern over a concentrated window. His cross-ticker track record shows 20 prior open-market buys with an average 90-day return of -10.3% and a 22.22% win rate, indicating a history of purchases that have not consistently delivered positive outcomes at the 90-day horizon.

10% owner Mosseri purchases 33,442 shares ($269.5K) over 2 days at $8.06-$8.11, raising stake by 1.1%

Mosseri Marlio Charles, a 10% owner, executed two separate purchases totaling 33,442 shares for $269,532.04 on 2025-06-17 and 2025-06-18 at an average price of $8.06 per share. His post-transaction holdings of 2,976,203 shares now represent a 1.1% increase from prior position. The company is currently unprofitable with net income of $-5,332,000.00, and the stock has declined 19.1% over the prior 30 days and 26.0% from its 52-week high of $10.98. His cross-ticker track record shows 0 of 20 prior buys were well-timed on a 90-day basis (90d win rate 20.00%, avg 90d return -12.1%), though his same-ticker history at NVCT shows recent positive 30-day outcomes (+8.9% on 2025-05-12; +2.3% on three purchases on 2025-05-08), with this most recent purchase outcome not yet measurable.

10% owner Mosseri Marlio Charles bought 21,167 shares of NVCT at $8.11 on 2025-05-12; aggressive accumulation pattern in unprofitable biotech stock.

Mosseri purchased 21,167 shares on 2025-05-12 at $8.11, adding to a concentrated position that now totals 2,942,761 shares (2.94M shares). This transaction is part of a rapid accumulation sequence: the insider executed 5 separate purchases at NVCT between 2025-05-07 and 2025-05-12, suggesting deliberate position building over consecutive trading days. The company reported a net loss of $-5,332,000.00 ($-5.3M) over its most recent full fiscal year, and the stock currently trades at $8.43—approximately -23.2% from its 52-week high of $10.98. Across the insider's broader cross-ticker buy history, his average 90-day return has been -14.9% with a 90-day win rate of only 16.67%, indicating a weak track record of purchasing at opportune moments. The timing and intensity of purchases in an unprofitable company warrant close observation, particularly given the gap between transaction price and the 52-week highs.

10% owner Mosseri buys 27,411 shares across 3 days (May 6–8, 2025) for $235,647.22 at blended $8.60; stock now $8.99.

Mosseri Marlio Charles, a 10% owner, executed 8 separate purchases totaling 27,411 shares for $235,647.22 between May 6–8, 2025, at prices ranging from $8.40 to $8.65 (blended average $8.60). The current stock price of $8.99 represents a gain of approximately 4.5% from the blended transaction price. At the same-ticker level, his prior 5 NVCT purchases show mixed timing outcomes: the two most recent buys (Feb 2025 and Dec 2024) were followed by strong 90-day returns (+84.4% and +77.7%), while three earlier 2023 purchases each resulted in 90-day declines. The company remains unprofitable with net income of $-5,332,000.00 over the most recent full fiscal year, and the stock has declined 18.1% from its 52-week high of $10.98. The accumulation of 27,411 shares represents a 1.0% increase to his holdings (2.91M post-transaction), suggesting continued commitment to the position, though the modest size and recent unprofitability context limit confidence in forward returns.

10% owner Mosseri bought 240,000 shares at $5.00 (Feb 2025); prior NVCT buys show 0 of 4 measurable outcomes positive at 90 days.

Mosseri Marlio Charles, a 10% owner, purchased 240,000 shares for $1,200,000.00 at $5.00 on 2025-02-07, increasing his holdings to 2,884,121 shares. This occurs while the stock trades at $6.29, down 42.8% from its 52-week high of $11.00 and off 41.0% over the past 90 days, suggesting the purchase price sits near recent support. However, his track record at NVCT shows a stark pattern: across 5 prior trades at this ticker, zero of 4 completed 90-day outcomes were positive, with prior buys from July 2023 returning -35.4% to -39.2% at the 90-day horizon. The company posted a net loss of $4,153,000.00 in its most recent full fiscal year, indicating ongoing operational challenges despite the 9.1% addition to his holdings. The timing and price alone do not offset the evidence that this insider's prior accumulation activity at NVCT has consistently coincided with subsequent declines, raising questions about the informational advantage of this purchase.

10% owner Mosseri Marlio Charles buys 17,000 shares of NVCT at $4.70; stock down 55.7% from 52-week high, unprofitable company.

Mosseri purchased 17,000 shares on 2024-12-13 at $4.70 in an unprofitable company with net income of $-4,153,000.00 and a market cap of $94,093,138.51. The stock has declined 26.8% in the 90 days preceding this transaction and currently trades at $4.87, down 55.7% from its 52-week high of $11.00. His prior five purchases at NVCT (conducted in July 2023) showed no instances of well-timed entry: each produced negative 90-day returns ranging from -35.4% to -39.2%. This purchase occurs during a period of sustained weakness and extends a pattern of unfavorable timing outcomes on this specific security.